CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 186 enrolled
Drug / intervention
ASC-J9 cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00525499
NCT00525499Phase 2Completed

A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Dose-Ranging Clinical Study to Evaluate the Safety and Efficacy of ASC-J9 Cream Applied Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris

AndroScience Corp·interventional·Posted Sep 5, 2007·Updated Nov 23, 2011

In Brief

A Phase 2 clinical trial evaluating ASC-J9 cream and placebo for Acne Vulgaris. Completed, enrolled 186 participants across 10 sites.

Detailed Summary

The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating acne.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 5, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.8 years ago

Interventions

ASC-J9 creamdrug

Topical application to the face twice daily for 12 weeks.

placebodrug

vehicle control applied topically twice daily for 12 weeks